Last reviewed · How we verify
ASKP1240
ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme.
ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma.
At a glance
| Generic name | ASKP1240 |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Drug class | PI3Kδ inhibitor |
| Target | PI3Kδ |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PI3Kδ, ASKP1240 is thought to modulate B-cell receptor signaling and potentially treat various B-cell malignancies.
Approved indications
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory marginal zone lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients (PHASE2)
- A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis (PHASE2)
- A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation (PHASE1)
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (PHASE2)
- Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects (PHASE1)
- Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASKP1240 CI brief — competitive landscape report
- ASKP1240 updates RSS · CI watch RSS
- Astellas Pharma Global Development, Inc. portfolio CI